Mogamulizumab Reference: HY-P99253 Mogamulizumab (KW-0761) is a defucosylated humanized recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL).
Elosulfase alfa Reference: HY-108794 Elosulfase alfa (BMN 110) is a recombinant form of human N-acetylgalactosamine-6-sulfatase (GALNS). Elosulfase alfa is used as an enzyme replacement therapy for mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A syndrome.
Tusamitamab Reference: HY-P99054 Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative).
Otlertuzumab Reference: HY-P99212 Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research.
Lucatumumab Reference: HY-P99167 Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research.
Timigutuzumab Reference: HY-P99558 Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer.